Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:CAR_T-cell_therapy
|
| gptkbp:advocacy |
required for participation
engaged in research discussions |
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:2018 gptkb:2019 active ongoing Phase 1 Phase 2 Cellectis overall response rate overall survival progression-free survival open-label clinicaltrials.gov to be determined. |
| gptkbp:clinical_trial_results_publication |
forthcoming
|
| gptkbp:collaboration |
gptkb:Servier
|
| gptkbp:collaborations |
academic institutions
|
| gptkbp:collection |
ongoing throughout trial
|
| gptkbp:commercialization_status |
not yet commercialized
|
| gptkbp:developed_by |
Cellectis
|
| gptkbp:dosage_form |
single infusion
|
| gptkbp:duration |
variable
|
| gptkbp:eligibility |
relapsed/refractory B-cell malignancies
|
| gptkbp:events |
12 months
|
| gptkbp:funding |
public and private sources
|
| gptkbp:future_prospects |
exploring combination therapies
|
| https://www.w3.org/2000/01/rdf-schema#label |
UCART19
|
| gptkbp:invention |
patented
|
| gptkbp:investigator_initiated_studies |
possible
|
| gptkbp:investment |
oncology therapeutics
|
| gptkbp:is_effective_against |
under investigation
|
| gptkbp:is_monitored_by |
required during treatment
|
| gptkbp:is_tested_for |
CD19 expression
|
| gptkbp:manufacturing_process |
GMP-compliant
|
| gptkbp:mechanism_of_action |
T-cell activation
genetically modified T-cells |
| gptkbp:objective |
evaluate safety and efficacy
|
| gptkbp:part_of |
Cellectis' UCART platform
|
| gptkbp:patient_population |
hematological malignancies
|
| gptkbp:provides_guidance_on |
outpatient
|
| gptkbp:publication |
peer-reviewed journals
|
| gptkbp:regulatory_compliance |
investigational
not yet approved |
| gptkbp:related_products |
yes
|
| gptkbp:related_to |
ALL (Acute Lymphoblastic Leukemia)
NHL (Non-Hodgkin Lymphoma) |
| gptkbp:research |
conducted in mice
|
| gptkbp:research_areas |
oncology
|
| gptkbp:research_ethics_approval |
obtained
|
| gptkbp:research_focus |
allogeneic CAR T-cell therapy
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_features |
under evaluation
|
| gptkbp:side_effect |
cytokine release syndrome
neurotoxicity |
| gptkbp:target_audience |
pediatric patients
adult patients |
| gptkbp:targets |
gptkb:CD19
|
| gptkbp:treatment |
monitored regularly
standardized remission induction assessed at follow-up visits |
| gptkbp:treatment_innovation |
part of CAR T-cell advancements
|
| gptkbp:used_for |
treatment of B-cell malignancies
|